x min read

Pharma Stock Updates: Horizon Pharma PLC (NASDAQ:HZNP), NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Galena Biopharma Inc (NASDAQ:GALE)

Pharma Stock Updates: Horizon Pharma PLC (NASDAQ:HZNP), NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Galena Biopharma Inc (NASDAQ:GALE)
Written by
Joel Najarian
Published on
October 14, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Horizon Pharma PLC (NASDAQ:HZNP), a biopharmaceutical company, provided late Monday an update on the opportunities for ACTIMMUNE (interferon gamma-1b), which is currently approved by the FDA to treat two ultra-rare orphan diseases, Chronic Granulomatous Disease (CDG) and severe, malignant osteopetrosis (SMO). The update was given at the company's analysts and investors meeting being conducted in King of Prussia, PA to coincide with the Children's Hospital of Philadelphia 7th Annual Friedreich's Ataxia (FA) Symposium.Horizon Pharma PLC (NASDAQ:HZNP) said that ACTIMMUNE is currently being used by approximately 270 patients for CGD and SMO. The company also reported results fom a Phase 2 clinical study in Friedreich's Ataxia patients, which is showed strong efficacy signal. HZNP estimates that ACTIMMUNE could potentially achieve $500 million or greater in peak annual net sales opportunity if approved by the FDA for FA along with increased penetration in its currently approved indications in CGD and SMO. FA is a debilitating, life-shortening, degenerative, neuro-muscular disorder that affects an estimated 4,000 to 5,000 individuals in the U.S. and 15,000 worldwide, according to Friedreich's Ataxia Research Alliance (FARA) . There is currently no approved FDA treatment for FA.NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) on Tuesday said it will present case histories on a recently launched eye care product, i-Lid Cleanser, to the American Academy of Ophthalmology meeting Oct.18-21. NBY, a developer of non-antibiotic anti-infective medicines, will discuss the use of i-Lid Cleanser for chronic conditions such as blepharitis (chronically inflamed eyelids), gland dysfunction (eye dryness) and for preparing the eye for surgical procedures. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) said its i-Lid cleaner is FDA approved, and includes substances released by white blood cells to fight microbial invaders, and that many eye doctors are using i-Lid Cleanser routinely in preparation for cataract surgery.Galena Biopharma Inc (NASDAQ:GALE) disclosed it received a new patent from Japan. The biopharmaceutical company developing and commercializing innovative, targeted oncology treatments The notice of allowance said it received a notice from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry (IHC) level of 1+ or 2+, or a fluorescence in situ hybridization (FISH) rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena Biopharma Inc (NASDAQ:GALE) lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.